[go: up one dir, main page]

KR937000640A - Live vaccine - Google Patents

Live vaccine

Info

Publication number
KR937000640A
KR937000640A KR1019920702407A KR920702407A KR937000640A KR 937000640 A KR937000640 A KR 937000640A KR 1019920702407 A KR1019920702407 A KR 1019920702407A KR 920702407 A KR920702407 A KR 920702407A KR 937000640 A KR937000640 A KR 937000640A
Authority
KR
South Korea
Prior art keywords
microorganism
protein
attenuated
dna sequence
encoding
Prior art date
Application number
KR1019920702407A
Other languages
Korean (ko)
Other versions
KR100202771B1 (en
Inventor
두간 고르단
조지 찰스 이안
에스테니오 호르매쉬 카를로스
스투아르트 존슨 캐빈
네빌 채드필드 스티븐
Original Assignee
엘. 디. 젠킨스
더 웰컴 파운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909007194A external-priority patent/GB9007194D0/en
Application filed by 엘. 디. 젠킨스, 더 웰컴 파운데이션 리미티드 filed Critical 엘. 디. 젠킨스
Publication of KR937000640A publication Critical patent/KR937000640A/en
Application granted granted Critical
Publication of KR100202771B1 publication Critical patent/KR100202771B1/en

Links

Abstract

내용 없음.No content.

Description

생 백신Live vaccine

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 htrA 유전자의 DNA 염기서열 및 이 유전자가 암호하는 단백질의 아미노산 서열이다.FIG. 1 shows the DNA sequence of the htrA gene and the amino acid sequence of the protein encoded by the gene.

제2도는 42℃ 이상의 온도 및 산소 라디칼에 대한 에스. 티피뮤리움(S. typhimjurium) htrA 돌연변이체 046의 민감도를 나타낸다.Figure 2 shows the S. for temperatures and oxygen radicals above 42 ° C. S. typhimjurium shows the sensitivity of htrA mutant 046.

Claims (16)

환경스트레스에 반응하여 제조되는 단백질을 암호하는 미생물의 DNA 서열 또는 상기 단백질을 암호하는 DNA의 발현을 조절하는 미생물의 DNA 서열을 돌연변이 시킴으로써 해당미생물을 약독화시키며 상기 미생물은 이중 항원을 암호하는 DNA를 발현시킬 수 있는 능력을 갖는 것을 특징으로 하는 면역예방용으로 사용하기 위한 약독화된 미생물.Attenuates the microorganism by mutating the DNA sequence of a microorganism encoding a protein produced in response to environmental stress or the DNA sequence of a microorganism controlling the expression of the DNA encoding the protein, and the microorganism attenuates DNA encoding a double antigen. An attenuated microorganism for use in immunoprevention, characterized by having the ability to express it. 제1항에 있어서, 상기 단백질은 열충격 단백질, 영양분 고갈 단백질, 독성 스트레스 단백질 및 대사 곤란 단백질로 부터 선택된 것을 특징으로 하는 약독화된 미생물.The attenuated microorganism of claim 1, wherein the protein is selected from a heat shock protein, a nutrient depleting protein, a toxic stress protein, and a difficult metabolic protein. 제2항에 있어서, 상기 단백질이 열충격 단백질인 것을 특징으로 하는 약독화된 미생물.The attenuated microorganism of claim 2, wherein the protein is a heat shock protein. 제3항에 있어서, 상기 단백질 htrA 유전자에 의해 암호된 것을 특징으로 하는 약독화된 미생물.The attenuated microorganism of claim 3, wherein the protein is encoded by the htrA gene. 제1항에 있어서, 돌연변이는 결손 돌연변이 또는 삽입 돌연변이인 것을 특징으로 하는 약독화된 미생물.The attenuated microorganism of claim 1, wherein the mutation is a deletion mutation or an insertion mutation. 제1항에 있어서, 미생물이 박테리아인 것을 특징으로 하는 약독화된 미생물.The attenuated microorganism of claim 1, wherein the microorganism is a bacterium. 제6항에 있어서, 박테리아 살모넬라(Salmonella속, 보르데텔라(Bordetella)속, 비브리오(Vibrio)속, 해모필러스(Haemophilus)속, 및 에스케리키아(Escherichia)속으로부터 선택된 것을 특징으로 하는 약독화된 미생물.Attenuated according to claim 6, characterized in that it is selected from the genus Salmonella, Bordetella, Vibrio, Haemophilus, and Escherichia. Microorganisms. 제7항에 있어서, 살모넬라 박테리움은 살모넬라 티피(S. typhi), 살모넬라 티피뮤리움(S. typhimurium), 살모넬라 엔테리티디스(S. enteritidis) 및 살모넬라 콜레라수이스(S. cholesrasuis)로 부터 선택된 것을 특징으로 하는 약독화된 미생물.The method of claim 7, wherein the Salmonella bacterium is selected from Salmonella typhi, Salmonella typhimurium, Salmonella enteritidis and Salmonella cholera suis. Attenuated microorganisms, characterized in that. 제1항에 있어서, 약독화가 또한 제2의 DNA 서열에 있는 돌연변이에 의해 야기되는 것을 특징으로 하는 약독화된 미생물.The attenuated microorganism of claim 1, wherein the attenuation is also caused by a mutation in the second DNA sequence. 제9항에 있어서, 제2의 DNA 서열에 있는 돌연변이가 방향족 아미노산의 생합성 경로에 관여하는 DNA 서열에 있는 것을 특징으로 하는 약독화된 미생물.10. The attenuated microorganism of claim 9, wherein the mutation in the second DNA sequence is in a DNA sequence involved in the biosynthetic pathway of the aromatic amino acid. 제10항에 있어서, 방향족 아미노산의 생합성 경로에 관여하는 DNA 서열이 aroC, aroA 및 aroD로부터 선택되는 것을 특징을하는 약독화된 미생물.The attenuated microorganism of claim 10, wherein the DNA sequence involved in the biosynthetic pathway of the aromatic amino acid is selected from aroC, aroA, and aroD. 제1항에 있어서, 이종 항원을 암호하는 DNA를 발현시킬 수 있는 약독화된 미생물.The attenuated microorganism of claim 1, wherein the attenuated microorganism is capable of expressing DNA encoding a heterologous antigen. 제1내지 12항중 어느 한 항의 약독화된 미생물의 유효량 및 약학적으로 허용가능한 이들을 위한 담체를 함유하는 백신.A vaccine containing an effective amount of the attenuated microorganism of any one of claims 1 to 12 and a pharmaceutically acceptable carrier therefor. 제13항에 있어서, 경구투여용 백신.The vaccine of claim 13 for oral administration. 미생물에 감염된 숙주의 예방적치료 방법에 있어서, 상기 숙주에 제13항의 백신을 유효량 투여하는 것을 포함하는 방법.A method of prophylactic treatment of a host infected with a microorganism, the method comprising administering to the host an effective amount of the vaccine of claim 13. 제1항의 미생물의 제조방법에 있어서, 상기 방법은 환경의 스트레스에 반응하여 생성되는 단백질을 암호하는 상기 미생물의 DNA 서열, 또는 상기 단백질을 암호하는 DNA의 발현을 조절하는 상기 미생물의 DNA 서열에 a) 전이성 유전자에 의한 돌연변이를 생성하거나 또는 b) 환경 스트레스에 반응하여 생성되는 단백질을 암호하는 DNA 서열, 또는 상기 단백질을 암호하는 DNA 서열의 발현을 조절하는 DNA 서열이 결합된 벡터로 상기 미생물을 형질감염시키고, 이때 상기 서열은 비복귀 돌연변이를 함유하며, c) 원하는 미생물을 선택하기 위해 스크리닝하는 단게를 포함하는 방법.The method according to claim 1, wherein the method comprises a DNA sequence of the microorganism encoding a protein produced in response to environmental stress, or a DNA sequence of the microorganism regulating the expression of DNA encoding the protein. B) transducing the microorganism with a vector combining a DNA sequence encoding a protein produced in response to environmental stress or a DNA sequence regulating the expression of the DNA sequence encoding the protein. Infecting, wherein said sequence contains a non-returning mutation, and c) screening to select the desired microorganism. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920702407A 1990-03-30 1991-03-28 Vaccine for preventive treatment of host against microbial infection KR100202771B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909007194A GB9007194D0 (en) 1990-03-30 1990-03-30 Live vaccines
GB9007194.5 1990-03-30
GB9007194,5 1990-03-30

Publications (2)

Publication Number Publication Date
KR937000640A true KR937000640A (en) 1993-03-15
KR100202771B1 KR100202771B1 (en) 1999-06-15

Family

ID=10673583

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702407A KR100202771B1 (en) 1990-03-30 1991-03-28 Vaccine for preventive treatment of host against microbial infection

Country Status (19)

Country Link
US (2) US5804194A (en)
EP (1) EP0524205B1 (en)
JP (1) JP3054440B2 (en)
KR (1) KR100202771B1 (en)
AT (1) ATE157397T1 (en)
CA (1) CA2079463C (en)
DE (1) DE69127440T2 (en)
DK (1) DK0524205T3 (en)
ES (1) ES2106776T3 (en)
GB (1) GB9007194D0 (en)
GR (1) GR3025258T3 (en)
HU (1) HU217776B (en)
IE (1) IE911037A1 (en)
IL (1) IL97720A (en)
MY (1) MY130001A (en)
NZ (1) NZ237616A (en)
TW (1) TW205567B (en)
WO (1) WO1991015572A1 (en)
ZA (1) ZA912397B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662908A (en) * 1985-07-31 1997-09-02 The Board Of Trustees Of The Leland Stanford Jr. University Invasive microorganisms
AU664360B2 (en) * 1991-03-05 1995-11-16 Wellcome Foundation Limited, The Expression of recombinant proteins in attenuated bacteria
WO1993018165A1 (en) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Microorganisms having attenuated invasiveness
EP0659086B1 (en) * 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
DE69429723T2 (en) 1993-06-04 2002-09-26 Whitehead Institute For Biomedical Research, Cambridge STRESS PROTEINS AND THEIR USE
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5796671A (en) 1996-03-01 1998-08-18 Wahlstrom; Sven E. Dynamic random access memory
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2298840A1 (en) 1997-08-05 1999-02-18 Stressgen Biotechnologies Corporation Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
CU22661A1 (en) * 1997-12-30 2001-04-27 Cnic Ct Nac Investigaciones NEW VACCINE CANDIDATES OF VIBRIO CHOLERAE AND METHOD OF OBTAINING
CA2321101C (en) 1998-02-20 2014-12-09 University Of Miami Modified heat shock protein-antigenic peptide complex
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
ES2286905T3 (en) 1998-12-02 2007-12-01 University Of Maryland, Baltimore PLASMID STABILIZATION SYSTEM FOR THE SUPPLY OF ANTIGENS.
US8076130B2 (en) 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
FR2787810B1 (en) 1998-12-24 2002-10-31 Inst Nat De La Rech Agronomique Inra POSITIVE GRAM BACTERIA WITHOUT HTRA PROTEASIC ACTIVITY, AND USES THEREOF
JP2003504074A (en) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション Induction of a Th1-like response in vitro
WO2001051081A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
JP2004505894A (en) 2000-06-02 2004-02-26 ユニバーシティー　オブ　コネティカット　ヘルス　センター Complex of α (2) macroglobulin and antigen molecule for immunotherapy
MXPA02012858A (en) 2000-06-26 2004-04-20 Stressgen Biotechnologies Corp Human papilloma virus treatment.
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
AU2002247084B2 (en) 2001-02-05 2007-01-04 Nventa Biopharmaceuticals Corporation Hepatitis B virus treatment
ITRM20010295A1 (en) * 2001-05-30 2002-12-02 Stresstech S R L METHOD FOR OBTAINING NON-VIRULENT PATHOGENIC MICRO-ORGANISMS THROUGH A MODIFICATION OF THE PHYSICAL AND / OR DYNAMIC STATE OF THEIR BI-MEMBRANES
EP1536829A4 (en) 2001-08-20 2006-05-31 Univ Connecticut Health Ct METHODS FOR THE PREPARATION OF STRESS OR ALPHA-2-MACROGLOBULIN PROTEIN COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
UA100370C2 (en) 2006-12-11 2012-12-25 Мериал Лимитед METHOD OF VACCINATION OF BIRDS AGAINST SALMONELL
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
CA2718884C (en) 2008-03-20 2016-11-22 University Of Miami Heat shock protein gp96 vaccination and methods of using same
IL214246B (en) * 2011-07-21 2018-08-30 Shafferman Avigdor Bacillus anthracis htra -defective-derived vaccines
EP3131575B1 (en) 2014-04-15 2024-05-08 Griffith University Group a streptococcus vaccine
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
KR20220152402A (en) 2019-11-25 2022-11-15 그리피스 유니버시티 Immunogenic proteins against gonococcal infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337314A (en) * 1979-05-23 1982-06-29 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
EP0300035B1 (en) * 1987-01-30 1995-05-10 The President And Fellows Of Harvard College Periplasmic protease mutants of escherichia coli
US4895717A (en) * 1987-07-10 1990-01-23 The United States Of America As Represented By The Secretary Of Agriculture Revertant serotype 1 Marek's disease vaccine
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines

Similar Documents

Publication Publication Date Title
KR937000640A (en) Live vaccine
Dong et al. Role of RpoS in virulence of pathogens
Tacket et al. Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection
Main-Hester et al. Coordinate regulation of Salmonella pathogenicity island 1 (SPI1) and SPI4 in Salmonella enterica serovar Typhimurium
Garcia-del Portillo et al. Role of acid tolerance response genes in Salmonella typhimurium virulence
Park et al. Functional characterization of two type III secretion systems of Vibrio parahaemolyticus
Duan et al. Flagella and bacterial pathogenicity
Merkel et al. Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis
Deiwick et al. Environmental regulation of Salmonella pathogenicity island 2 gene expression
KR100202771B1 (en) Vaccine for preventive treatment of host against microbial infection
Janda et al. Pathogenic properties of Edwardsiella species
Santander et al. Fur-regulated iron uptake system of Edwardsiella ictaluri and its influence on pathogenesis and immunogenicity in the catfish host
Mayo et al. Antibiograms, serotypes, and plasmid profiles of Pseudomonas aeruginosa associated with corneal ulcers and contact lens wear
Lynch et al. Expression and role of superoxide dismutases (SOD) in pathogenic bacteria
Robbe‐Saule et al. Identification of a non‐haem catalase in Salmonella and its regulation by RpoS (σS)
Colquhoun et al. Temperature dependent siderophore production in Vibrio salmonicida
Kwaga et al. A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys
Mellata et al. Characterization of the contribution to virulence of three large plasmids of avian pathogenic Escherichia coli χ7122 (O78: K80: H9)
Wang et al. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909
KR890010200A (en) Wax
Hernanz Moral et al. Molecular characterization of the Aeromonas hydrophila aroA gene and potential use of an auxotrophic aroA mutant as a live attenuated vaccine
Sakai Significance of extracellular protease for growth of a heterotrophic bacterium, Aeromonas salmonicida
Rodríguez-Morales et al. Salmonella enterica serovar Typhimurium ompS1 and ompS2 mutants are attenuated for virulence in mice
Fuller et al. A riboflavin auxotroph of Actinobacillus pleuropneumoniae is attenuated in swine
Okuda et al. The toxR gene of Vibrio (Listonella) anguillarum controls expression of the major outer membrane proteins but not virulence in a natural host model

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920930

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19960328

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920930

Comment text: Patent Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980708

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19981222

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19990322

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19990323

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20020313

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20030311

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20040310

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20050309

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20060313

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20070319

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20080310

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20090311

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20100310

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20111210

Termination category: Expiration of duration